Jpmorgan Chase & Co »

Avenue Therapeutics shares owned by Jpmorgan Chase & Co

Quarter-by-quarter ownership of Avenue Therapeutics (ATXI) shares owned by Jpmorgan Chase & Co from 13F filings

Historical chart of Jpmorgan Chase & Co investment in Avenue Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Avenue Therapeutics held by Jpmorgan Chase & Co consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Avenue Therapeutics by Jpmorgan Chase & Co

Quarter filed Position value Share count Share price at filing
2024-09-30 $3 1 3.00
2024-06-30 $4 1 4.00

More positions owned by Jpmorgan Chase & Co

Microsoft Corp Common (MSFT)
Nvidia Corporation Common (NVDA)
Apple Common (AAPL)
Amazon Common (AMZN)
Spdr S&p 500 Etf Ser 1 S&p Common (SPY)
Meta Platforms Common (META)
Eli Lilly & Co Common (LLY)
Alphabet Common (GOOG)
Unitedhealth Group Common (UNH)
Mastercard Incorporated Common (MA)
Vanguard Index Fds S&p 500 Etf Common (VOO)
Ishares Core S&p 500 Etf Fund (IVV)
Vanguard Total Intl Bond Etf Fund (BNDX)
Broadcom Common (AVGO)
Exxon Mobil Corp Common (XOM)

View all positions for Jpmorgan Chase & Co

Top funds holding Avenue Therapeutics

Armistice Capital
Moss Adams Wealth Advisors
Tower Research Capital
Wells Fargo & Company
Bank of America Corporation
Emfo
Jpmorgan Chase & Co

View all funds holding Avenue Therapeutics